Effects of dietary supplementation with epigallocatechin-3-gallate on weight loss, energy homeostasis, cardiometabolic risk factors and liver function in obese women: randomised, double-blind, placebo-controlled clinical trial
| Autor: | Pilar Alcorta, Eider Larrarte, Juan Mielgo-Ayuso, Idoia Labayen, Lurdes Barrenechea, Javier Margareto |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
medicine.medical_specialty Diet Reducing Bilirubin Medicine (miscellaneous) Blood lipids Biology Antioxidants Camellia sinensis Catechin Body Mass Index Young Adult chemistry.chemical_compound Insulin resistance Double-Blind Method Risk Factors Weight loss Internal medicine medicine Humans Resting energy expenditure Obesity Metabolic Syndrome Nutrition and Dietetics Plant Extracts Cholesterol Middle Aged medicine.disease Plant Leaves Endocrinology Liver chemistry Spain Dietary Supplements Female Anti-Obesity Agents Liver function Insulin Resistance medicine.symptom Energy Metabolism Body mass index |
| Zdroj: | British Journal of Nutrition. 111:1263-1271 |
| ISSN: | 1475-2662 0007-1145 |
| DOI: | 10.1017/s0007114513003784 |
| Popis: | The aim of the present study was to examine the effects of green tea epigallocatechin-3-gallate (EGCG) on changes in body composition, energy and substrate metabolism, cardiometabolic risk factors and liver function enzymes after an energy-restricted diet intervention in obese women. In the present randomised, double-blind, placebo-controlled study, eighty-three obese (30 kg/m2>BMI 2) pre-menopausal women consumed 300 mg/d of EGCG or placebo (lactose). We measured body weight and adiposity (dual-energy X-ray absorptiometry), energy expenditure and fat oxidation rates (indirect calorimetry), blood lipid levels (TAG, total cholesterol, LDL-cholesterol and HDL-cholesterol), insulin resistance, C-reactive protein and liver function markers (aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, γ-glutamyltransferase, urea, bilirubin and 2-keto[1-13C]isocaproate oxidation) before and after the intervention in the EGCG and control groups. We did not find any significant difference in the changes in body weight ( − 0·3 kg, 95 % CI − 5·0, 4·3), fat mass ( − 0·7 kg, 95 % CI − 3·5, 2·1), energy (0·3 kJ/kg per d, 95 % CI − 3·1, 2·7) and fat ( − 0·1 g/min, 95 % CI − 0·03, 0·01) metabolism, homeostasis assessment model for insulin resistance (0·2, 95 % CI − 0·2, 0·7), total cholesterol ( − 0·21 mmol/l, 95 % CI − 0·55, 0·13), LDL-cholesterol ( − 0·15 mmol/l, 95 % CI − 0·50, 0·20), TAG ( − 0·14 mmol/l, 95 % CI − 0·56, 0·29) and liver function markers between the EGCG and control groups. In conclusion, the present results suggest that dietary supplementation with 300 mg/d of EGCG for 12 weeks did not enhance energy-restricted diet-induced adiposity reductions, and did not improve weight-loss-induced changes in cardiometabolic risk factors in obese Caucasian women. The intake of 300 mg/d of EGCG for 12 weeks did not cause any adverse effect on liver function biomarkers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|